Advanced Medical Solutions vs Lantheus: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Advanced Medical Solutions Group plc (AMS.LSE)

Q3 202615 Jul – 13 Aug 2026

▲1

Shareholders approve H.B. Fuller takeover AMS shareholders voted in favour of H.B. Fuller's recommended cash buyout at meetings on 12 August. That clears a major hurdle, making the deal more likely to complete by year-end and anchoring the share price near the offered terms.
This is the single biggest new event and the main force now setting AMS's price.
Octopus keeps trimming its stake Octopus Investments disclosed its holding fell from 8.66% to 8.28% to 8.07% across July, selling shares each time. The stake is large, but the steady selling suggests it is reducing exposure rather than betting on a higher price.
Shows a major holder's behaviour, a real counterweight to deal optimism.
Broker Investec's routine share dealings Investec, AMS's joint broker, repeatedly bought and sold AMS shares in near-equal amounts around 280p. This is normal market-making tied to its advisory role, not a signal about AMS's health, so it adds little to the bigger picture.
Explains the other recurring disclosure and why it is not a real driver.

July 202615 Jul – 13 Aug 2026

▲1

Shareholders approve H.B. Fuller takeover AMS shareholders voted in favour of H.B. Fuller's recommended cash buyout at meetings on 12 August. That clears a major hurdle, making the deal more likely to complete by year-end and anchoring the share price near the offered terms.
This is the single biggest new event and the main force now setting AMS's price.
Octopus keeps trimming its stake Octopus Investments disclosed its holding fell from 8.66% to 8.28% to 8.07% across July, selling shares each time. The stake is large, but the steady selling suggests it is reducing exposure rather than betting on a higher price.
Shows a major holder's behaviour, a real counterweight to deal optimism.
Broker Investec's routine share dealings Investec, AMS's joint broker, repeatedly bought and sold AMS shares in near-equal amounts around 280p. This is normal market-making tied to its advisory role, not a signal about AMS's health, so it adds little to the bigger picture.
Explains the other recurring disclosure and why it is not a real driver.

Latest15 Jul – 13 Aug 2026

▲1

Shareholders approve H.B. Fuller takeover AMS shareholders voted in favour of H.B. Fuller's recommended cash buyout at meetings on 12 August. That clears a major hurdle, making the deal more likely to complete by year-end and anchoring the share price near the offered terms.
This is the single biggest new event and the main force now setting AMS's price.
Octopus keeps trimming its stake Octopus Investments disclosed its holding fell from 8.66% to 8.28% to 8.07% across July, selling shares each time. The stake is large, but the steady selling suggests it is reducing exposure rather than betting on a higher price.
Shows a major holder's behaviour, a real counterweight to deal optimism.
Broker Investec's routine share dealings Investec, AMS's joint broker, repeatedly bought and sold AMS shares in near-equal amounts around 280p. This is normal market-making tied to its advisory role, not a signal about AMS's health, so it adds little to the bigger picture.
Explains the other recurring disclosure and why it is not a real driver.

Q3 202626 Jun – 14 Aug 2026

▲2▼1

Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.
The buyout is the single biggest force driving LNTH's price and future value.
FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.
A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.
FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.
This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.

July 202626 Jun – 14 Aug 2026

▲2▼1

Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.
The buyout is the single biggest force driving LNTH's price and future value.
FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.
A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.
FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.
This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.

Latest26 Jun – 14 Aug 2026

▲2▼1

Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.
The buyout is the single biggest force driving LNTH's price and future value.
FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.
A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.
FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.
This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.